AUSTIN, Texas--(BUSINESS WIRE)--Introgen Therapeutics, Inc. (NASDAQ:INGN), a developer of targeted molecular therapies for cancer, today announced financial results for the quarter and nine months ended September 30, 2008, and highlighted recent corporate developments.
